Details
Category: Volume 08 Issue 01 January 2020
Hits: 1302

Title: Comparative Study of Induction Chemotherapy Followed by Concurrent Weekly Chemoradiotherapy vs 3-Weekly Chemoradiotherapy in Locally Advanced Head and Neck Cancer

Authors: Dr Pukhraj Sadh, Dr Neeti Sharma, Dr H.S.kumar, Dr S.L. Jakhar, Dr Ranjeet Ram Jat

 DOI: https://dx.doi.org/10.18535/jmscr/v8i1.04

Abstract

The purpose of the study was to assess difference in the treatment response and toxicity profile  among two groups of unresectable locally advanced head and neck malignancies receiving concurrent weekly chemoradiotherapy  vs 3-weekly chemoradiotherapy after completing neoadjuvant chemotherapy.

50 patients received neoadjuvant chemotherapy (inj. paclitaxel 175 mg/m2 D1, Cisplatin 80mg/m2 divided in 2 days & inj 5FU 1gm/m2 iv d1 & d2).Then randomly allotted into above two groups to receive 66 Gy fractionated RT along with concurrent weekly inj Cisplatin 40mg/m2 in day1 versus RT along with concurrent 3 weekly inj Cisplatin 80mg/m2 devided in day1 & day2. Disease response was evaluated by RECIEST criteria.

All patients tolerated treatment well, no major adverse effects were monitored in two groups. There was no significant statistical difference in treatment response, which was found 84% vs 80% in concurrent weekly CTRT vs 3-weekly CTRT. however toxicity profile was higher in 3-weekly concurrent CTRT group. The  6 months PFS were 88% and 85.6% in CTRT and RT alone groups respectively; ( p value>0.05)

Keywords: Chemoradiotherapy, Induction chemotherapy, Unresectable locally advanced head and neck cancer.

References

  1. Rodriguez CP, Adelstein DJ. Survival trends in head and neck Cancer: opportunities for improving outcomes. Oncologist. 2010;15:921–3.
  2. Jakobsen KK, Grønhøj C, Jensen DH, Karnov KKS, Agander TK, Specht L, et al. Increasing incidence and survival of head and neck cancers in Denmark: a nation-wide study from 1980 to 2014. Acta Oncol (Madr). 2018:1–9.
  3. Megwalu UC, Sirjani D, Devine EE. Oropharyngeal squamous cell carcinoma incidence and mortality trends in the United States, 1973-2013. Laryngoscope. 2018;128:1582–8.
  4. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798–804.
  5. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92–8.
  6. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.N Engl J Med 2003;349:2091–8.
  7. Adelstein DJ, Sharan VM, Earle AS, et al. Simultaneous versus sequential combined technique therapy for squamous cell head and neck cancer. Cancer. 1990;65(8):1685–1691.
  8. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21(1):92–98.
  9. Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013;31(7):845–852.
  10. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. CA Cancer J Clin 2011;61:69-90.
  11. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al., Eds. SEER Cancer Statistics Review, 1975–2004. Bethesda, MD: National Cancer Institute; 2007. Available from: http://seer.cancer. gov/csr/1975_2004/. [Last accessed on 2017 Jul].
  12. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimation of worldwide burden of cancer in 2008. Globocan 2008 Int J Cancer 2010;127:2893-917.
  13. Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. Journal of Clinical Oncology. 2003; 21:92-98.
  14. NCCN Clinical Practice Guidelines in Oncology:Head and Neck Cancers, Version 1, 2015.
  15. Pignon JP, le Maître A, Maillard E, Bourhis J, MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiotherapy and Oncology. 2009; 92:4-14.
  16. Adelstein DJ, Li Y, Adams GL, et al (2003). An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoraditherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol, 21, 92-8.
  17. Bachaud JM, Cohen-Jonathan E, Alzieu C, et al (1996). Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys, 36, 999-1004.
  18. Bernier J, Domenge C, Ozsahin M, et al (2004). Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med, 350, 1945-52.

Corresponding Author

Dr Neeti Sharma

Professor and Head, Radiation Oncology Department, ATRCTRI, S.P. Medical College, Bikaner